/wp-content/uploads/logo-300x63.png00eallison/wp-content/uploads/logo-300x63.pngeallison2026-04-20 15:12:132026-04-21 12:49:51Synthekine Presents Updated Clinical and Translational Data Demonstrating Strong Activity for STK-012 in First-Line Non-Squamous NSCLC in Oral Presentation at AACR 2026
/wp-content/uploads/logo-300x63.png00eallison/wp-content/uploads/logo-300x63.pngeallison2026-03-17 12:29:212026-03-17 12:48:04Synthekine Announces AACR 2026 Oral Presentation of Updated Phase 1a/1b Clinical and Translational Data for STK 012 in First Line Nonsquamous NSCLC with Features of Immunotherapy Resistance
/wp-content/uploads/logo-300x63.png00eallison/wp-content/uploads/logo-300x63.pngeallison2026-02-25 12:17:372026-02-25 13:10:30Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
/wp-content/uploads/logo-300x63.png00eallison/wp-content/uploads/logo-300x63.pngeallison2026-02-20 10:32:432026-02-20 14:42:07Synthekine Appoints Biotechnology and Pharmaceutical Industry Veteran John A. Orwin as Chair of its Board of Directors
